Publicaciones (14) Publicaciones de Emilia Balboa Beltrán

2022

  1. Efectividad de las medidas no farmacológicas dirigidas a los lugares de trabajo en el control de la diseminaciónde la COVID-19

    Conselleria de Sanidade

  2. Efectividad de las medidas no farmacológicas dirigidas al comercio en el control de la diseminación de la COVID-19

    Conselleria de Sanidade

2015

  1. Delimiting allelic imbalance of TYMS by allele-specific analysis

    Medicine (United States), Vol. 94, Núm. 27, pp. e1091

  2. Long Survival and Severe Toxicity under 5-Fluorouracil-Based Therapy in a Patient with Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS

    Mayo Clinic Proceedings, Vol. 90, Núm. 9, pp. 1298-1303

2014

  1. A novel stop mutation in the vascular endothelial growth factor-C gene (VEGFC) results in Milroy-like disease

    Journal of Medical Genetics, Vol. 51, Núm. 7, pp. 475-478

  2. The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine

    Colorectal Cancer - Surgery, Diagnostics and Treatment

2013

  1. Distinct mechanism of formation of the 48, XXYY karyotype

    Molecular Cytogenetics, Vol. 6, Núm. 1

2012

  1. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

    Cancer Chemotherapy and Pharmacology, Vol. 69, Núm. 6, pp. 1591-1599

  2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 1, pp. 138-144

2011

  1. Evolutionary analyses of entire genomes do not support the association of mtdna mutations with ras/mapk pathway syndromes

    PLoS ONE, Vol. 6, Núm. 4

  2. Role of Tumor Tissue Analysis in Rectal Cancer Pharmacogenetics. Rectal Cancer - A Multidisciplinary Approach to Management

    Rectal Cancer - A Multidisciplinary Approach to Management (InTech)

  3. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer

    Pharmacogenomics, Vol. 12, Núm. 3, pp. 433-442

2010

  1. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response

    Pharmacogenomics, Vol. 11, Núm. 6, pp. 747-761

2009

  1. Analysis of pharmacogenetic biomarkers in rectal patients trated with chemoradiotherapy

    Journal of Clinical Oncology